Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Harbour BioMed and CTTQ Partner to Discover New Cancer/Immune Drugs

publication date: May 9, 2019

Harbour BioMed will partner with Chia Tai Tianqing (CTTQ), a Lianyungang pharma, to discover and develop next-gen biologics for therapeutic targets in oncology and immunology. Harbour will use its discovery platform, including its transgenic mouse technology, to generate fully human antibodies, while CTTQ will contribute its preclinical development expertise. CTTQ will be responsible for clinical development of all candidates in China and the EU; Harbour will have rights to the US and the rest of the world. Each company will pay royalties on sales to the other. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital